<ARIA>
I bought some a while ago..too early..been away from the 'puter and market today..nice to see it bounced up today..
They are presenting the following early stuff on the mTOR inhibitor..
Some analysts point to NFKB litigation with Eli Lilly over Xigris and Evista? and also 'resurrection' of Src/Abl platform but I haven't any idea what this program is about nor what ARIA's case is re: LLY.maybe someone else does? I hear the Loonie bro's put some premium not only on an ASCO bounce but these other 2 issues and ASH updates in Dec..
Monday, 5/16/2005, 8:00 - 12:00pm A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas Presenter: Sant P Chawla, MD
General Poster Sessions Sarcoma
Monday, 5/16/2005, 1:00 - 5:00pm Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor Presenter: Victor M Rivera, PhD
Poster Discussion Sessions Developmental
Therapeutics: Molecular Therapeutics
Sunday, 5/15/2005, 8:00 - 12:00pm Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor Presenter: Apurva A Desai, MD
Molecular Therapeutics
Sunday, 5/15/2005, 1:00 - 5:00pm Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan Presenter: Kamalesh K Sankhala, MD[ PET scans are becoming more and more prominent in trials..good to see this
Poster Discussion Sessions Sarcoma
Tuesday, 5/17/2005, 8:00 - 12:00pm A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies Presenter: Eric Feldman, MD
|
